Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...

Beyond Cancer announced that the Israeli Ministry of Health, or IMOH, has approved the use of Low Volume UNO in a Phase 1b clinical trial of LV ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

AI-081 is a differentiated bispecific antibody with robust cooperative interactions between PD1 and VEGFDosing of first patient in BIPAVE-001 ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, ...

New insights into the impact of checkpoint inhibitors on the immune system may enhance cancer treatment strategies. A ...

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering ...